Hinova Pharmaceuticals, Inc. Class ASSE: 688302

"HINOVA PHARMACEUTICALS INC."Announcement on Resolutions of the 18th Meeting of the 2nd Board of Directors

Aug 27, 2026 · Issued by Hinova Pharmaceuticals, Inc. Class A via Shanghai Stock Exchange

Announcement on Resolutions of the 18th Meeting of the 2nd Board of Directors

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Hinova Pharmaceuticals, Inc. Class A

"HINOVA PHARMACEUTICALS INC."Voluntary Disclosure Announcement on Receipt of Notice of Approval for Initiation of a Phase III Clinical Trial of Deuterated Enzalutamide Soft Capsules for High-risk Biochemical Recurrence (BCR) Prostate CancerJul 16
Announcement on Reply to Inquiry Letter for Information Disclosure Supervision of 2025 Annual ReportJun 27
Announcement on Voluntary Disclosure of Final Analysis Results Obtained from Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)Jun 16
Announcement on Resolutions of the 2025 Annual General MeetingMay 16

All Hinova Pharmaceuticals, Inc. Class A news releases